Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo Chronic lymphocytic leukemia (CLL) is characterized by the deregulated accumulation and persistence of B lymphocytes in the blood. Although the exact causes of CLL are unknown, the evasion of apoptosis through the aberrant expression of B-cell lymphoma 2 (BCL2)-family proteins is a common feature. 1 A class of compounds, termed Bcl-2 homology domain 3 (BH3) mimetics, has been developed to directly inhibit BCL2 proteins and selectively kill tumor cells. To date, the most successful of these compounds are the BCL2/BCLXL inhibitors ABT-737 2 and ABT-263 (navitoclax), 3 , as well as the BCL2-specific inhibitor ABT-199. 4 Results from early clinical trials with navitoclax have demonstrated single-agent efficacy in patients with relapsed or refractory CLL. 5 However, there was heterogeneity in response rates between patients and dose-limiting toxicities, including thrombocytopenia and neutropenia, which prevented further dose escalation. In addition, CLL cells residing within various microenvironments (for example, lymph nodes and bone marrow) are resistant to BCL2 inhibitors. This resistance results from the upregulation of additional BCL2 proteins, such as BCLXL, MCL1 and BFL1, the latter two of which are not inhibited by navitoclax, and therefore protect the leukemia cells from apoptosis. 6 Additional drugs are needed to enhance the efficacy of navitoclax. Here, we demonstrate that gossypol overcomes stroma-mediated resistance to ABT-737 without enhancing the sensitivity of normal lymphocytes and platelets.
The BH3-only protein, NOXA, is a potent inhibitor of MCL1 and BFL1, 7 but has recently been recognized to inhibit BCLXL with lower affinity. 8 Therefore, compounds which induce NOXA may inhibit MCL1, BFL1 and BCLXL, thus overcoming the resistance to navitoclax. We previously reported that six putative BH3 mimetics do not directly inhibit BCL2 in cells, but instead activate the integrated stress response, and induce NOXA. 9 Of these six compounds, gossypol has advanced into clinical trials in a racemically purified form (AT-101). 10 We hypothesized that gossypol, through the induction of NOXA, would sensitize CLL cells to ABT-737.
CLL cells from consented patients were incubated ex vivo with up to 10 mM ABT-737, which is comparable to the peak plasma concentration of navitoclax in a Phase I trial. 5 Apoptosis, as assessed by chromatin condensation, (or caspase cleavage of poly (ADP-ribose) polymerase; data not shown) was induced within 6 h as previously noted. 9 The CLL samples were highly sensitive to ABT-737, as a single agent, with most cells undergoing apoptosis between 10 and 100 nM ( Figure 1a ). Gossypol alone (5-20 mM) induced NOXA, but had minimal impact on apoptosis within this time frame. Importantly, gossypol sensitized the cells to ABT-737, with most cells now undergoing apoptosis between 1 and 10 nM.
Coculture of CLL cells on the stromal cells can mimic the protective microenvironment seen in the patients, and promote resistance to ABT-737 and navitoclax. Different stroma have variously been reported to increase the expression of MCL1, BFL1 and BCLXL. 6, 11 We hypothesized that gossypol might overcome stroma-mediated resistance to ABT-737 by inducing NOXA. We used a coculture system, whereby CLL cells were incubated with fibroblasts expressing CD154 (CD40L). 12 Following 24-h coculture, BCLXL was markedly increased in all the CLL samples; there was a variable increase in BFL1 and no significant increase in MCL1 (Figure 1b ). BCL2 expression was unchanged. In agreement with a previous report, 6 we observed at least 100-fold resistance, with most cells requiring 1-10 mM ABT-737 to induce apoptosis (Figure 1c) . Importantly, we found that gossypol resensitized the CLL cells to ABT-737 in a concentration-dependent manner, with apoptosis again occurring at 10-100 nM ABT-737. To determine whether this sensitization was unique to CLL cells, we incubated normal lymphocytes with ABT-737 and gossypol ex vivo. Normal lymphocytes were significantly resistant to ABT-737 alone and in combination with gossypol ( Figure 1d) , with even less apoptosis occurring than in the CLL cells incubated on stroma. As thrombocytopenia was the major dose-limiting toxicity of navitoclax in clinical trials, 5 we determined whether gossypol increases ABT-737-mediated apoptosis in platelets. Caspase-mediated cleavage of gelsolin, a marker for apoptosis, was only observed when the platelets were incubated with 10 mM ABT-737 (Figure 1e) . Importantly, the addition of gossypol did not increase gelsolin cleavage, indicating that it did not sensitize the platelets to ABT-737.
It is interesting that CLL cells incubated on stroma are killed by 10 mM ABT-737 as a single agent, which is the same concentration that induces apoptosis in the platelets. As platelets are dependent on BCLXL, and BCLXL appears to be the predominantly induced BCL2 protein in the CLL cells on stroma, this suggests that the resistance in CLL cells is dependent on BCLXL. This would be consistent with the recent data demonstrating that ABT-737 is less effective at inhibiting BCLXL than BCL2. 13 In addition, the fact that gossypol does not kill platelets suggests that it is not acting as a direct BCLXL inhibitor, but may instead require NOXA-induction for BCLXL inhibition. A previous report that gossypol inhibits BCLXL may therefore be explained by the induction of NOXA, which was simultaneously observed but not considered the mechanism of BCLXL inhibition. 14 It has been reported that nuclear factor-kB inhibitors can prevent the development of resistance to ABT-737 mediated by CD154. 6 However, this approach would fail to kill CLL cells in the lymph node that are already resistant. Other drugs, such as dasatinib and fludarabine, have been shown to resensitize CLL cells to ABT-737 in this stroma coculture model, but these combinations required 24-48 h, and only partially overcame resistance. 15 In contrast, the gossypol plus ABT-737 combination reported here overcame resistance almost completely in 6 h. To the best of our knowledge, the efficacy demonstrated here with this drug combination is far superior to any previously published. 12 CLL cells were then gently removed from the stroma and passed through an 8-m filter to remove any residual stromal cells. Purified CLL cells were lysed (urea lysis buffer) and analyzed for MCL1, BCLXL, BFL1, BCL2 and actin (loading control) via western blotting. (c) Gossypol resensitizes CLL cells to ABT-737 in a stroma coculture model. Isolated CLL cells were cocultured on CD154-expressing stroma for 24 h, and then incubated for 6 h as indicated and scored for % survival (n ¼ 5-11). (d) Normal lymphocytes are resistant to ABT-737 and gossypol combinations. Lymphocytes were isolated from healthy individuals via ficol extraction, treated for 6 h as indicated and scored for % survival (n ¼ 2). (e) Gossypol does not increase platelet death induced by ABT-737. Platelets from a healthy donor were isolated via centrifugation and treated for 6 h as indicated. Caspase-dependent cleavage of gelsolin was used as a marker of apoptosis in platelets. Dimethyl sulfoxide (0.1%) was used as a vehicle control.
Taken together, these findings identify a novel drug combination, which is able to overcome resistance to a BCL2 inhibitor in a clinically relevant CLL model. Importantly, normal lymphocytes and platelets are resistant to the combination of ABT-737 and gossypol, which offers a therapeutic window to selectively kill CLL cells. It is therefore plausible that this combination may kill resistant CLL cells within the stromal niche in vivo, and may improve clinical outcome. As both the gossypol and navitoclax have been tested in humans, this data support the notion of a combination trial in patients with CLL. Both drugs have demonstrated toxicity when administered on a chronic daily basis, 5, 10 but the data presented here suggest acute treatment might be effective, and thereby avoid the undesirable toxicities.
Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells Like other cancers, chronic lymphocytic leukemia (CLL) is initiated and/or progresses as a consequence of concurrent chromosomal abnormalities and recurrent somatic mutations. Using nextgeneration sequencing, a short list of recurrent mutations in various genes has been identified in CLL.
1,2 One of these genes is SF3B1 that encodes a key component of the mRNA splicing machinery. SF3B1 mutations were initially discovered in myelodysplastic syndromes (MDSs) and in some other solid tumors, suggesting it is having an important role in cancer biology. In CLL, SF3B1 mutations are associated with disease subtype, 1 progression, 3,4 chemotherapy resistance 4, 5 and overall patient survival. 6 However, the biological consequences of SF3B1 mutations in CLL pathogenesis are largely unknown. Here, we find that acquisition of mutations in SF3B1 eventually leads to the loss of the wild-type copy of this gene, suggesting the mutant SF3B1 gene has a dominant role in clonal evolution. We also provide evidence that SF3B1 mutations are potentially oncogenic, supporting the possibility that mutant SF3B1 is an attractive druggable therapeutic target.
Wang et al. 1 reported that SF3B1 mutations are more prevalent in CLL patients with 11q deletion. We randomly picked 73 cryopreserved peripheral blood mononuclear cell (PBMC) samples with 11q deletion from our CLL patient cohort, and screened for SF3B1 mutations (Supplemental Methods). We identified eight patients with various missense mutations including five patients with K700E (2098A4G), one with K649E (1945A4G), one with K622E (1866G4T) and one with K666E (1996A4G). These mutations have been observed by others in CLL, MDS and other cancers. 1, 2, 7 We also found that SF3B1 mutations are only present in a sub-allelic-fraction (ranging from 10 to 45%) of bulk DNA samples (Figure 1a) .
Cancer progression is typically characterized by the emergence and outgrowth of newly evolved subclones. By analyzing the allelic burden of SF3B1 mutations in CLL using the Sanger Accepted article preview online 20 May 2013; advance online publication, 11 June 2013
